TransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 16.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 903,086 shares of the company's stock after acquiring an additional 128,474 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 2.69% of TransMedics Group worth $56,307,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Clear Creek Financial Management LLC purchased a new position in TransMedics Group in the 4th quarter valued at about $352,000. Vaughan Nelson Investment Management L.P. raised its position in shares of TransMedics Group by 9.9% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company's stock valued at $22,547,000 after buying an additional 32,605 shares during the last quarter. Baillie Gifford & Co. lifted its stake in shares of TransMedics Group by 14.9% during the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company's stock valued at $16,824,000 after buying an additional 34,947 shares during the period. State of Michigan Retirement System acquired a new stake in TransMedics Group during the fourth quarter worth approximately $6,734,000. Finally, Peregrine Capital Management LLC boosted its position in TransMedics Group by 64.0% during the fourth quarter. Peregrine Capital Management LLC now owns 66,140 shares of the company's stock worth $4,124,000 after acquiring an additional 25,814 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Trading Up 0.1%

TMDX traded up $0.09 during trading on Wednesday, hitting $128.62. 598,706 shares of the company's stock were exchanged, compared to its average volume of 1,357,511. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The stock has a 50 day moving average price of $91.84 and a 200 day moving average price of $77.79. The firm has a market cap of $4.35 billion, a P/E ratio of 136.83 and a beta of 1.91. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm had revenue of $143.54 million during the quarter, compared to analysts' expectations of $123.39 million. During the same period in the prior year, the company earned $0.35 EPS. The firm's revenue was up 48.2% on a year-over-year basis. As a group, analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Piper Sandler reissued an "overweight" rating and set a $125.00 price target (up previously from $105.00) on shares of TransMedics Group in a research note on Friday, May 9th. Canaccord Genuity Group reiterated a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a research report on Tuesday, March 11th. Oppenheimer lifted their price target on TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, TransMedics Group currently has a consensus rating of "Moderate Buy" and an average target price of $126.70.

Insider Transactions at TransMedics Group

In other news, Director David Weill sold 732 shares of the business's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total transaction of $90,680.16. Following the transaction, the director now directly owns 12,134 shares of the company's stock, valued at approximately $1,503,159.92. The trade was a 5.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward M. Basile sold 6,000 shares of the firm's stock in a transaction on Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director now directly owns 732 shares of the company's stock, valued at approximately $84,641.16. The trade was a 89.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.00% of the company's stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.